Researchers at Diaceutics uncovered the need for faster laboratory testing turnaround times (TAT) in an abstract accepted for publication by the European Hematology Association (EHA) for its annual meeting in June 2019. The abstract, entitled “FLT3 Testing in Relapsed Acute Myeloid Leukemia Setting Is Becoming Increasingly Common, But Laboratory Turnaround Times (TAT) May Be a Barrier to Treatment With Second Generation FLT3 Inhibitors,” analyzed the FLT3 testing behavior in relapsed acute myeloid leukemia (AML) over the course of a year.
The researchers discovered an increase in awareness of the need for retesting in FLT3 and the need for faster TAT in the relapsed setting. However, the TAT results did not demonstrate an improvement in actual TAT, with the average TAT remaining suboptimal at 12.6 days., This may be due to the lack of an approved FLT3 inhibitor for second–line treatment in Europe. Lab TAT will be a key metric to monitor over the coming 12 to 18 months.
For more information on these findings, contact email@example.com.